Pulmonology Center of Excellence

Supporting patients living with a rare pulmonology condition

Orsini’s Pulmonology Center of Excellence launched in 2014 with our first program for idiopathic pulmonary fibrosis (IPF). Today we support multiple pulmonology programs across several rare conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Pulmonology Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Patient-Centered Care

Experience compassionate care that prioritizes patients and their families. Our team supports patients of all ages, from infants to the elderly, extending care to the entire care team.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Pulmonology Conditions Supported

Explore the rare pulmonology conditions Orsini supports below.

About Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis is a progressive lung disease characterized by the gradual thickening and scarring of lung tissue. This scarring hinders the lungs’ ability to efficiently transfer oxygen into the bloodstream, resulting in debilitating symptoms. Individuals with IPF often experience shortness of breath, a persistent dry cough, fatigue, unexplained weight loss, and muscle and joint aches. The term ‘idiopathic’ indicates an unknown cause, adding to the complexity of the condition.

IPF Therapies Supported

Full Name	Esbriet® (pirfenidone)
Drug	Esbriet
Manufacturer	Genentech
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of idiopathic pulmonary fibrosis (IPF)
Disease	Idiopathic Pulmonary Fibrosis (IPF)
Therapeutic Area	Pulmonology
Enrollment Form Link	Enrollment Form
Phone Number	800-355-9366
Fax Number	877-358-9246
Product Website	esbriethcp.com

Full Name	Ofev® (nintedanib)
Drug	Ofev
Manufacturer	Boehringer Ingelheim
Route of Administration	Oral
Site of Care	Home
Approved Indication	Treatment of idiopathic pulmonary fibrosis (IPF) in adults, treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype in adults, or slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Disease	Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)
Therapeutic Area	Pulmonology
Enrollment Form Link	Ofev Enrollment Form
Phone Number	800-373-1452
Fax Number	888-975-1456
Product Website	ofev.com

Full Name	pirfenidone
Drug	Pirfenidone
Manufacturer	Generic
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of idiopathic pulmonary fibrosis (IPF)
Disease	Idiopathic Pulmonary Fibrosis (IPF)
Therapeutic Area	Pulmonology
Enrollment Form Link	Pirfenidone Enrollment Form
Phone Number	800-355-9366
Fax Number	877-358-9246
Product Website

About Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

Systemic sclerosis interstitial lung disease is a complex and progressive condition that arises as a complication of systemic sclerosis, an autoimmune disorder. This disease manifests as fibrosis and inflammation in the lungs, impairing their normal function. Common symptoms include breathlessness, persistent cough, and diminished lung capacity. Understanding this interplay between the body’s autoimmune response and lung damage helps in navigating the journey of living with SSc-ILD.

SSc-ILD Therapies Supported

Full Name	Ofev® (nintedanib)
Drug	Ofev
Manufacturer	Boehringer Ingelheim
Route of Administration	Oral
Site of Care	Home
Approved Indication	Treatment of idiopathic pulmonary fibrosis (IPF) in adults, treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype in adults, or slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Disease	Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)
Therapeutic Area	Pulmonology
Enrollment Form Link	Ofev Enrollment Form
Phone Number	800-373-1452
Fax Number	888-975-1456
Product Website	ofev.com